132 related articles for article (PubMed ID: 37132604)
1. NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy.
Li G; Xu Y; Kong X; Gu L; Qin Y; Wu L
Chem Commun (Camb); 2023 May; 59(42):6343-6346. PubMed ID: 37132604
[TBL] [Abstract][Full Text] [Related]
2. An NAD(P)H:Quinone Oxidoreductase 1 Responsive and Self-Immolative Prodrug of 5-Fluorouracil for Safe and Effective Cancer Therapy.
Zhang X; Li X; Li Z; Wu X; Wu Y; You Q; Zhang X
Org Lett; 2018 Jun; 20(12):3635-3638. PubMed ID: 29847952
[TBL] [Abstract][Full Text] [Related]
3. Human NAD(P)H:quinone oxidoreductase type I (hNQO1) activation of quinone propionic acid trigger groups.
Mendoza MF; Hollabaugh NM; Hettiarachchi SU; McCarley RL
Biochemistry; 2012 Oct; 51(40):8014-26. PubMed ID: 22989153
[TBL] [Abstract][Full Text] [Related]
4. NAD(P)H:Quinone Oxidoreductase 1 (NQO1) as a Therapeutic and Diagnostic Target in Cancer.
Zhang K; Chen D; Ma K; Wu X; Hao H; Jiang S
J Med Chem; 2018 Aug; 61(16):6983-7003. PubMed ID: 29712428
[TBL] [Abstract][Full Text] [Related]
5. Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery system.
Volpato M; Abou-Zeid N; Tanner RW; Glassbrook LT; Taylor J; Stratford I; Loadman PM; Jaffar M; Phillips RM
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3122-30. PubMed ID: 18089707
[TBL] [Abstract][Full Text] [Related]
6. Research advances in NQO1-responsive prodrugs and nanocarriers for cancer treatment.
Yang X; Duan J; Wu L
Future Med Chem; 2022 Mar; 14(5):363-383. PubMed ID: 35102756
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of NAD(P)H: Quinone oxidoreductase (NQO1)-activated prodrugs of 23-hydroxybetulinic acid with enhanced antitumor properties.
Zhu H; Lu L; Zhu W; Tan Y; Duan Y; Liu J; Ye W; Zhu Z; Xu J; Xu S
Eur J Med Chem; 2022 Oct; 240():114575. PubMed ID: 35803175
[TBL] [Abstract][Full Text] [Related]
8. NAD(P)H:Quinone Acceptor Oxidoreductase 1 (NQO1) Activatable Salicylamide H
Roy NJ; Save SN; Sharma VK; Abraham B; Kuttanamkuzhi A; Sharma S; Lahiri M; Talukdar P
Chemistry; 2023 Sep; 29(51):e202301412. PubMed ID: 37345998
[TBL] [Abstract][Full Text] [Related]
9. NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance.
Li X; Liu Z; Zhang A; Han C; Shen A; Jiang L; Boothman DA; Qiao J; Wang Y; Huang X; Fu YX
Nat Commun; 2019 Jul; 10(1):3251. PubMed ID: 31324798
[TBL] [Abstract][Full Text] [Related]
10. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
Siegel D; Yan C; Ross D
Biochem Pharmacol; 2012 Apr; 83(8):1033-40. PubMed ID: 22209713
[TBL] [Abstract][Full Text] [Related]
11. Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
Winski SL; Swann E; Hargreaves RH; Dehn DL; Butler J; Moody CJ; Ross D
Biochem Pharmacol; 2001 Jun; 61(12):1509-16. PubMed ID: 11377380
[TBL] [Abstract][Full Text] [Related]
12. Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.
den Braver-Sewradj SP; den Braver MW; Toorneman RM; van Leeuwen S; Zhang Y; Dekker SJ; Vermeulen NPE; Commandeur JNM; Vos JC
Chem Res Toxicol; 2018 Feb; 31(2):116-126. PubMed ID: 29281794
[TBL] [Abstract][Full Text] [Related]
13. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
14. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential.
Colucci MA; Moody CJ; Couch GD
Org Biomol Chem; 2008 Feb; 6(4):637-56. PubMed ID: 18264564
[TBL] [Abstract][Full Text] [Related]
15. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.
Reinicke KE; Bey EA; Bentle MS; Pink JJ; Ingalls ST; Hoppel CL; Misico RI; Arzac GM; Burton G; Bornmann WG; Sutton D; Gao J; Boothman DA
Clin Cancer Res; 2005 Apr; 11(8):3055-64. PubMed ID: 15837761
[TBL] [Abstract][Full Text] [Related]
16. Intracellular Enzyme-Responsive Profluorophore and Prodrug Nanoparticles for Tumor-Specific Imaging and Precise Chemotherapy.
Pei Q; Lu S; Zhou J; Jiang B; Li C; Xie Z; Jing X
ACS Appl Mater Interfaces; 2021 Dec; 13(50):59708-59719. PubMed ID: 34879654
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
Qu Y; Zhang C; Ma X; Gao Y; Liu J; Wu L
Bioorg Med Chem; 2020 Dec; 28(24):115821. PubMed ID: 33091789
[TBL] [Abstract][Full Text] [Related]
18. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
19. NAD(P)H:quinone oxidoreductase-1-dependent and -independent cytotoxicity of potent quinone Cdc25 phosphatase inhibitors.
Han Y; Shen H; Carr BI; Wipf P; Lazo JS; Pan SS
J Pharmacol Exp Ther; 2004 Apr; 309(1):64-70. PubMed ID: 14718602
[TBL] [Abstract][Full Text] [Related]
20. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity.
Beall HD; Winski S; Swann E; Hudnott AR; Cotterill AS; O'Sullivan N; Green SJ; Bien R; Siegel D; Ross D; Moody CJ
J Med Chem; 1998 Nov; 41(24):4755-66. PubMed ID: 9822546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
